Paces of Costly Care: Rare Disease Drug Access in Canada.

Clicks: 451
ID: 89245
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #1 of 5 articles by views in medical anthropology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Pharmaceutical industry representatives and public drug plan managers hold competing visions of drug access, ones I theorize as "fast" and "slow" care paces. The relationship between free market imaginaries and population-based biopolitics is negotiated through these paces from within the flexible political category of rare disease. In this article, I explore expensive rare disease drug access in Canada's universal health system through a temporal lens. I show how two families navigate these powerful negotiations, asserting themselves as deserving of resources while finding ways to consider life and death outside of this clash between health system pragmatics and pharmaceutical promise.
Reference Key
mcguire2019pacesmedical Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors McGuire, Marlee;
Journal medical anthropology
Year 2019
DOI
10.1080/01459740.2019.1573229
URL
Keywords
value valorisation canada rare disease couverture universelle sanitaire l’accès aux medicaments maladies rares pharmaceutical access temporality temporalité universal health care

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.